Sensitivity to an inhibitor of translation elongation in solid and hematologic cancers

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Protein synthesis inhibitors offer a therapeutic strategy for cancers by targeting unstable oncoproteins.
• SVC112, a translation elongation inhibitor, previously demonstrated efficacy against Head and Neck Squamous Cell Carcinoma (HNSCC) stem cells and tumor xenografts post-radiation.

Purpose of the Study:

• To evaluate the standalone anti-cancer activity of SVC112 across diverse cancer cell lines.
• To identify molecular correlates of SVC112 sensitivity and resistance.
• To establish the predictive value of SVC112-induced apoptosis for therapeutic outcomes in preclinical models.

Main Methods:

• Screening of SVC112 efficacy across a panel of cancer cell lines with varying origins.
• Analysis of molecular markers, including basal expression of apoptosis/survival factors and c-Myc phosphorylation, in relation to SVC112 sensitivity.
• Assessment of tumor growth control and survival benefit in mouse xenograft models following SVC112 treatment.

Main Results:

• SVC112 exhibited a 1600-fold range in growth inhibition across different cancer cell lines, indicating variable sensitivity.
• Sensitivity in hematologic cancers correlated with basal expression of apoptosis/survival factors.
• Sensitivity in colorectal cancers correlated with c-Myc phosphorylation.
• SVC112-induced apoptosis was predictive of tumor growth control and survival benefit in vivo.

Conclusions:

• SVC112 demonstrates standalone anti-cancer activity, with sensitivity influenced by cancer-specific molecular profiles.
• The utility of translation inhibitors may depend on inherent cancer cell dependencies and post-translational modifications affecting oncogenic protein stability.
• SVC112 holds potential as a targeted cancer therapeutic, warranting further investigation into its predictive biomarkers.